Related Experiment Video
Updated: Aug 9, 2026
10:24
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
Adalimumab Therapy Reduces Treatment Burden in Multifocal Choroiditis/Punctate Inner Choroidopathy
Benjamin Ho1, Elmira Baghdasaryan2, Naomi R Goldberg2,3
1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
Ocular Immunology and Inflammation
|August 7, 2026
Summary
Adalimumab significantly reduced treatment burden for idiopathic multifocal choroiditis/punctate inner choroidopathy. This biologic therapy decreased steroid use, injections, and other immunomodulatory therapies while preserving vision.
Area of Science:
- Ophthalmology
- Immunology
- Retinal Diseases
Background:
- Idiopathic multifocal choroiditis (MFC) and punctate inner choroidopathy (PIC) are inflammatory retinal conditions.
- Current treatments often involve significant systemic or local immunosuppression, leading to treatment burden.
Purpose of the Study:
- To evaluate the efficacy of adalimumab (ADA) in reducing the overall treatment burden in patients with idiopathic MFC/PIC.
- To assess the impact of ADA on medication dosage, procedures, and disease flares.
Main Methods:
- Retrospective case series of patients with idiopathic MFC/PIC.
- Data collected included best-corrected visual acuity (BCVA), corticosteroid dosage, immunomodulatory therapy (IMT) use, anti-vascular endothelial growth factor (anti-VEGF) injections, and disease flares.
- Evaluations were performed at baseline, 12 months, and last follow-up.
Main Results:
- Twenty-five patients (41 eyes) were included with a mean follow-up of 51.4 months.
- Adalimumab therapy led to a significant reduction in prednisone dosage (15.76 mg/day to 0.23 mg/day, p<0.0001).
- There was a significant decrease in steroid/anti-VEGF injections (30 to 1, p<0.0001) and other IMT use (8 to 1, p<0.05).
Conclusions:
- Adalimumab demonstrated a significant steroid-sparing effect in patients with idiopathic MFC/PIC.
- The therapy helped preserve vision and reduce the need for other intensive treatments.
- Adalimumab effectively lowered the overall treatment burden associated with these conditions.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...